Real-world effect of vitrectomy combined with intravitreal conbercept for treatment of vitreous haemorrhage in proliferative diabetic retinopathy (QILIN I): a prospective cohort study

Retinal Diseases

Progression of diabetic retinopathy in a longitudinal real-world study of patients in primary care

BMC Ophthalmol

Lalwani G, Wykoff CC, Briggs J, Lin CY, Steffen V, Haskova Z

doi: 10.1186/s12886-025-04307-1

Retinal Diseases

Intravitreal Therapy in Adults Aged ≤50 Years: Etiologic Spectrum, Treatment Patterns and Visual Outcomes in a Real-World Cohort

J Clin Med

Rodríguez-Fernández CA, Oliver-Gutierrez D, Arnaiz A, Pablos T, Segura-Duch G, Zapata MÁ

doi: 10.3390/jcm15124508

Retinal Diseases

Associations between fenofibrate use and sight-threatening diabetic retinopathy in type 2 diabetes: UK real-world evidence

J Clin Endocrinol Metab

Tan L, Cooper JM, Gokhale K, Sainsbury C, Denniston AK, Toulis KA, Crowe FL, Nirantharakumar K, Wang J

doi: 10.1210/clinem/dgag367

Glaucoma and Ocular Pressure

Risk of Dementia in Type 2 Diabetes Patients with Open-Angle Glaucoma: Insights from a Nationwide Real-World Cohort Study

Am J Ophthalmol

Zhou J, Lee DA, Talebi Y, Wu G, Wu H

doi: 10.1016/j.ajo.2026.02.003

Retinal Diseases

Inflammatory biomarkers as prognostic tools for diabetic retinopathy progression: a prospective study

Diabetes Res Clin Pract

Johansen MS, Stidsen JV, Hansen AL, Dyg Johansen TS, Nielsen JS, Pedersen FN, Grauslund J, Olsen MH, Højlund K, Olesen TB

doi: 10.1016/j.diabres.2026.113195

Macular DiseasesRetinal Diseases

Tirzepatide and Reduced Risk of Diabetic Retinopathy and Related Complications: A Multicenter U.S. Cohort Study

Ophthalmology

Shah J, Razavi P, Festok M, Ahmed H, Mahrous MA, Kovacs KD, Kiss S

doi: 10.1016/j.ophtha.2026.01.013

Retinal Diseases

Looking Beyond Glycaemic Control: Real-World 12-Month Cardiometabolic and Retinopathy Outcomes Following Omnipod 5 Initiation in People With Type 1 Diabetes

Diabetes Obes Metab

McNally E, Goodman I, Morris R, Maliekkal J, Saeed D, Tan HW, Berry S, Elliott J, Iqbal A

doi: 10.1111/dom.71129

Retinal Diseases

Brolucizumab in the Treatment of Proliferative Diabetic Retinopathy: The CONDOR Randomized Clinical Trial

JAMA Ophthalmol

Wolf S, Chen Y, Li X, Shimura M, Sakamoto T, Wykoff CC, Emanuelli A, Salehi-Had H, Yan K, Kovacic L, Kim Y

doi: 10.1001/jamaophthalmol.2026.1008

Retinal Diseases

Real-world performance of an AI system for diabetic retinopathy screening

Sci Rep

Berrada L, Crenier L, Lytrivi M, Burniat A, Motulsky E, Cnop M

doi: 10.1038/s41598-026-37292-6

Related content

Progression of diabetic retinopathy in a longitudinal real-world study of patients in primary care

Intravitreal Therapy in Adults Aged ≤50 Years: Etiologic Spectrum, Treatment Patterns and Visual Outcomes in a Real-World Cohort

Associations between fenofibrate use and sight-threatening diabetic retinopathy in type 2 diabetes: UK real-world evidence

Risk of Dementia in Type 2 Diabetes Patients with Open-Angle Glaucoma: Insights from a Nationwide Real-World Cohort Study

Inflammatory biomarkers as prognostic tools for diabetic retinopathy progression: a prospective study

Tirzepatide and Reduced Risk of Diabetic Retinopathy and Related Complications: A Multicenter U.S. Cohort Study

Looking Beyond Glycaemic Control: Real-World 12-Month Cardiometabolic and Retinopathy Outcomes Following Omnipod 5 Initiation in People With Type 1 Diabetes

Brolucizumab in the Treatment of Proliferative Diabetic Retinopathy: The CONDOR Randomized Clinical Trial

Real-world performance of an AI system for diabetic retinopathy screening